Severe acute respiratory syndrome coronavirus 2 spike protein receptor-binding domain (SARS-CoV-2 S-RBD) (Omicron variant) (SARS-CoV-2 S-RBD (Omicron))

The SARS-CoV-2 spike protein receptor-binding domain (RBD) of the Omicron variant is a critical component of the viral surface glycoprotein responsible for mediating host cell entry [4, 12]. It functions by specifically binding to the human angiotensin-converting enzyme 2 (ACE2) receptor, which is the primary gateway for the virus to infect respiratory tissues [5, 10]. The Omicron variant (B.1.1.529) is distinguished by more than 15 mutations within this domain, including N501Y, K417N, and E484A, which collectively enhance its binding affinity for ACE2 while promoting immune evasion [9, 14, 15]. These structural changes allow the virus to bypass neutralizing antibodies generated by previous infections or first-generation vaccines, leading to increased transmissibility and breakthrough infections [9, 13]. As a result, the Omicron RBD is a central target for the development of updated bivalent mRNA vaccines and next-generation monoclonal antibodies like Sotrovimab and Bebtelovimab [10, 15]. Therapeutic strategies often focus on blocking the RBD-ACE2 interface to neutralize the virus and prevent the progression of COVID-19 [3, 6]. Monitoring mutations in this domain is critical for public health surveillance and the design of broad-spectrum antivirals [11, 16].

Other names

Omicron RBDB.1.1.529 receptor-binding domainSARS-CoV-2 S-RBD (Omicron)Omicron spike protein RBDSARS-CoV-2 Omicron RBD

Neutralization of viral infection by competitively binding to the receptor-binding domain, thereby preventing its interaction with the host cell receptor angiotensin-converting enzyme 2 (ACE2) and inhibiting viral entry [3, 10, 13].